By Colin Kellaher

Exact Sciences Corp. on Wednesday said it is in talks that could result in major changes to its Cologuard promotion agreement with Pfizer Inc. after the drugmaker scaled back promotional activity for the at-home colon-cancer screening test.

Exact said Pfizer recently cut the number of sales positions supporting its internal-medicine therapeutic area, and that it has hired about 400 of the sales representatives who were displaced by Pfizer, nearly doubling the size of its primary care field sales team to more than 850 representatives.

Exact, a Madison, Wis., molecular-diagnostics company, inked a Cologuard co-promotion agreement with New York-based Pfizer in late 2018, and the companies last year said they had extended the deal through 2022.

However, Exact on Wednesday said Pfizer is currently promoting Cologuard with a smaller team, and that its partner isn't making in-person sales calls in 41 states due to recent Covid-19 internal policies. Exact, meanwhile, said its newly expanded sales team is in the field and interacting with healthcare providers in person, focused solely on Cologuard initially.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 15, 2021 09:53 ET (13:53 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Pfizer.
Pfizer (NYSE:PFE)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Pfizer.